🇺🇸 FDA
Pipeline program

SALINE, Fazirsiran

TAK-999-3002

Phase 3 small_molecule active

Quick answer

SALINE, Fazirsiran for Alpha-1 Antitrypsin Deficiency-Associated Liver Disease is a Phase 3 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).

Program details

Company
Takeda Pharmaceuticals International AG
Indication
Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials